Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Dow
Medtronic
AstraZeneca

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)

Docket   Start Trial Date Filed 2011-03-31
Court District Court, D. Delaware Date Terminated 2013-08-09
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Defendant Referred To Mary Pat Thynge
Parties ALLERGAN INC.; HI-TECH PHARMACAL CO. INC.; KYORIN PHARMACEUTICAL CO. LTD.; LUPIN LIMITED; LUPIN PHARMACEUTICALS INC.; SENJU PHARMACEUTICAL CO. LTD.
Patents 4,551,456; 4,980,470; 5,880,283; 6,333,045
Attorneys Anuj K. Wadhwa; Brian P. Murray; Deanne M. Mazzochi; Harven DeShield; Jack B. Blumenfeld; Jeffrey Thomas Castellano; John C. Phillips , Jr.; John D. Polivick; John W. Shaw; Karen Elizabeth Keller; Maryellen Noreika; Megan C. Haney; Paul Molino; Tara Ragahavan; William A. Rakoczy
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Senju Pharmaceutical Co. Ltd. v. Lupin Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Senju Pharmaceutical Co. Ltd. v. Lupin Limited (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-03-31 1 United States Patent No. 6,333,045 (“the ‘045 Patent”) and United States Patent No. 5,880,283 (“the ‘283 … Allergan has listed the ‘045 Patent, the ‘283 Patent, and other patents in the “Approved Drug Products…283 Patent”) under 35 U.S.C. §27l(e)(2) and declaration of infringement of those same patents THE PARTIES…interest in the ‘045 Patent. 22. Allergan is the exclusive licensee of the ‘045 Patent for ophthalmic uses…Claim l of the ‘283 Patent claims gatifloxacin sesquihydrate. A copy of the ‘283 Patent is attached to this External link to document
2012-11-13 129 on the Pleadings that the Claims of U.S. Patent No. 6,333,045 Are Invalid and Not Infringed filed by Lupin…2011 9 August 2013 1:11-cv-00271 830 Patent Defendant District Court, D. External link to document
2012-11-14 131 on the Pleadings that the Claims of U.S. Patent No. 6,333,045 Are Invalid and Not Infringed. (Noreika,…2011 9 August 2013 1:11-cv-00271 830 Patent Defendant District Court, D. External link to document
2012-11-28 134 on the Pleadings that the Claims of U.S. Patent No. 6,333,045 are Invalid and Not Infringed by Allergan…2011 9 August 2013 1:11-cv-00271 830 Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Express Scripts
Johnson and Johnson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.